-
Addex Therapeutics, CMTA Join Forces To Develop Potential Treatment For Rare Neurological Disorder
Wednesday, September 22, 2021 - 7:17am | 299Read More...The Charcot–Marie–Tooth Association (CMTA), a philanthropic funder of CMT research worldwide, and Addex Therapeutics Ltd (NASDAQ: ADXN) have collaborated to investigate a potential therapy for CMT type 1A (CMT1A). Charcot-Marie-Tooth disease type 1A (CMT1A) is an...
-
Eton Pharmaceuticals Offloads Neurology Portfolio To Azurity Pharmaceuticals For $45M
Monday, February 8, 2021 - 10:28am | 310Read More...Eton Pharmaceuticals Inc (NASDAQ: ETON) has sold its neurology portfolio that includes lamotrigine (ET-105), zonisamide (ET-104), and topiramate (ET-101) product candidates, to Azurity Pharmaceuticals. The marketing applications for all three candidates are currently under...
